Rigel Pharmaceuticals, Inc. (RIGL)
Evaluation: Based on all recent filings, financial statements, and news.
See full evaluationAsk a question about Rigel Pharmaceuticals, Inc. (RIGL)
Go deeper and ask any question about RIGL
Company Performance
Current Price
as of Sep 13, 2024$13.70
P/E Ratio
N/A
Market Cap
$241.05M
Description
Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It discovers and develops novel, targeted drugs in the therapeutic areas of immunology, oncology and immune oncology. The firm focuses on intracellular signalling pathways and related targets that are critical to disease mechanisms. The company's products include Tavalisse, Fostamatinib and R835. Rigel Pharmaceuticals was founded by Donald G. Payan, James M. Gower, Thomas A. Raffin, Garry P. Nolan and Ronald B. Garren on June 14, 1996 and is headquartered in South San Francisco, CA.
Metrics
Overview
- HQSouth San Francisco, CA
- SectorHealth Technology
- IndustryPharmaceuticals: Major
- TickerRIGL
- Price$13.7+5.79%
Trading Information
- Market Cap$241.05M
- Float98.02%
- Average Daily Volume (1m)95,903
- Average Daily Volume (3m)527,265
- EPS-$0.81
Company
- Revenue$130.30M
- Rev Growth (1yr)37.03%
- Net Income-$1.03M
- Gross Margin92.38%
- EBITDA Margin2.88%
- EBITDA$1.06M
- EV$155.48M
- EV/Revenue1.19
- P/EN/A
- P/S1.85